Lantern Pharma Inc. Leverages AI to Revolutionize Oncology Drug Development

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company, is pioneering the use of artificial intelligence (AI) and machine learning in oncology drug development. Its proprietary RADR(R) platform, which harnesses over 200 billion oncology-specific data points, is setting new standards in the field. This innovative approach not only accelerates the drug development process but also dramatically reduces the associated costs, marking a significant leap forward in the fight against cancer.

The company is currently focusing its efforts on three lead drug candidates aimed at addressing some of the most difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and non-Hodgkin’s lymphoma (NHL). Through its Starlight Therapeutics initiative, Lantern Pharma is also venturing into the realm of brain and central nervous system (CNS) cancers, with a particular emphasis on pediatric cases. The FDA has acknowledged the potential of these endeavors by awarding several designations, such as Fast Track, Orphan Drug, and Rare Pediatric Disease status, which not only highlight the significance of Lantern Pharma's work but also expedite the regulatory process for its therapies.

What sets Lantern Pharma apart is its ability to transition drug programs from initial AI-based insights to first-in-human clinical trials in a mere 2-3 years, with an average cost of $2.5 million per program. This efficiency underscores the transformative potential of AI in oncology drug development. For further details on Lantern Pharma's innovative approach, visit https://ibn.fm/s1B45.